MX2021015500A - Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. - Google Patents

Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.

Info

Publication number
MX2021015500A
MX2021015500A MX2021015500A MX2021015500A MX2021015500A MX 2021015500 A MX2021015500 A MX 2021015500A MX 2021015500 A MX2021015500 A MX 2021015500A MX 2021015500 A MX2021015500 A MX 2021015500A MX 2021015500 A MX2021015500 A MX 2021015500A
Authority
MX
Mexico
Prior art keywords
pyrazines
glun2b receptor
substituted pyrazolo
receptor modulators
glun2b
Prior art date
Application number
MX2021015500A
Other languages
English (en)
Spanish (es)
Inventor
Curt Dvorak
Heather Coate
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2021015500A publication Critical patent/MX2021015500A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2021015500A 2019-06-14 2020-06-12 Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. MX2021015500A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962861681P 2019-06-14 2019-06-14
PCT/EP2020/066405 WO2020249802A1 (en) 2019-06-14 2020-06-12 Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators

Publications (1)

Publication Number Publication Date
MX2021015500A true MX2021015500A (es) 2022-02-10

Family

ID=71111400

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015500A MX2021015500A (es) 2019-06-14 2020-06-12 Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.

Country Status (10)

Country Link
US (2) US11214563B2 (cg-RX-API-DMAC7.html)
EP (1) EP3983413A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022536773A (cg-RX-API-DMAC7.html)
KR (1) KR20220024403A (cg-RX-API-DMAC7.html)
CN (1) CN114008052A (cg-RX-API-DMAC7.html)
AU (1) AU2020292994A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021024117A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143105A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021015500A (cg-RX-API-DMAC7.html)
WO (1) WO2020249802A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
AU2020290772A1 (en) 2019-06-14 2022-01-06 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
AU2020291188A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators
SG11202112407PA (en) 2019-06-14 2021-12-30 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピラゾロ-ピリジンアミド及びglun2b受容体調節因子としてのその使用
EP3983413A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
US20220324860A1 (en) 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
BR112021025132A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Carbamatos de piridina e seu uso como moduladores do receptor glun2b
EP4669318A1 (en) * 2023-02-23 2025-12-31 The Rockefeller University 1-ACYL-3-AMINOINDAZOLES FOR THE TREATMENT OF CYSTIC FIBROSIS
KR20250094560A (ko) 2023-12-15 2025-06-25 서울대학교산학협력단 GluN2B 억제제를 유효성분으로 포함하는 페닐케톤뇨증 및 고페닐알라닌혈증의 뇌기능 장애 예방, 개선 또는 치료용 조성물

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ288351B6 (en) 1990-06-07 2001-05-16 Astrazeneca Ab Nitrogenous heterocyclic compound, process of its preparation and use as well as a medicament containing thereof
GB9407447D0 (en) 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds
CA2262502C (en) 1996-07-31 2002-11-26 Nikken Chemicals Co., Ltd. 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same
WO2002000629A1 (en) 2000-06-26 2002-01-03 Merck & Co., Inc. Iminopyrimidine nmda nr2b receptor antagonists
US6610723B2 (en) 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
KR20040111445A (ko) 2002-03-28 2004-12-31 에자이 가부시키가이샤 신경퇴행성 질환 치료용 c─Jun N─말단 키나아제억제제로서의 7─아자인돌
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
CN1656079A (zh) 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
AU2004274403A1 (en) 2003-09-03 2005-03-31 Aventis Pharmaceuticals Inc. 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds
AU2005214375A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
EP1805142A4 (en) 2004-09-23 2009-06-10 Reddy Us Therapeutics Inc PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME
AU2005309566A1 (en) 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or Rho kinase
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
KR20100017372A (ko) 2007-05-25 2010-02-16 애보트 게엠베하 운트 콤파니 카게 향대사성 글루타메이트 수용체 2(mglu2 수용체)의 포지티브 조절자로서의 헤테로사이클릭 화합물
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
WO2009028543A1 (ja) 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 置換ピラゾール誘導体
WO2009058261A1 (en) 2007-10-31 2009-05-07 Merck & Co., Inc. Modulation of sleep with nr2b receptor antagonists
US20110053951A1 (en) 2008-03-27 2011-03-03 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
EP2298731A4 (en) 2008-06-25 2011-09-21 Takeda Pharmaceutical AMIDE COMPOUND
DK2308877T3 (da) 2008-08-05 2014-04-22 Daiichi Sankyo Co Ltd Imidazopyridin-2-on-derivater
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
KR101048448B1 (ko) 2008-11-21 2011-07-11 한국화학연구원 신규 피라졸로[4,3-b]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法
US8969342B2 (en) 2009-03-20 2015-03-03 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
WO2011022348A1 (en) 2009-08-18 2011-02-24 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid amide hydrolase
EP2579717A4 (en) 2010-06-09 2013-12-11 Merck Sharp & Dohme POSITIVE ALLOSTERIC MODULATORS OF MGLUR2
JP5990106B2 (ja) 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
JP2012188363A (ja) 2011-03-09 2012-10-04 Dainippon Sumitomo Pharma Co Ltd アザベンゾイミダゾロン誘導体
PH12014500239A1 (en) 2011-07-28 2014-03-31 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PL2570415T3 (pl) * 2011-09-19 2016-01-29 Sanofi Sa N-[4-(1H-pirazolo[3,4-b]pirazyn-6-ylo)-fenylo]-sulfonamidy i ich zastosowanie jako farmaceutyki
WO2013060029A1 (en) * 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp Allosteric modulators of metabotropic glutamate receptors
WO2013130855A1 (en) 2012-03-02 2013-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
CN105308049A (zh) 2013-01-29 2016-02-03 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
WO2014124651A1 (en) 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
TW201444820A (zh) 2013-03-13 2014-12-01 Abbvie Inc 吡啶cdk9激酶抑制劑
CN105073747B (zh) 2013-03-15 2017-06-06 普莱希科公司 杂环化合物及其应用
KR102307566B1 (ko) 2013-06-21 2021-10-05 제니쓰 에피제네틱스 리미티드 신규한 바이사이클릭 브로모도메인 억제제
JP6612751B2 (ja) 2013-07-31 2019-11-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Btkの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用
PT3180315T (pt) 2014-08-15 2020-05-27 Janssen Pharmaceuticals Inc Pirazoles
EP3180329B1 (en) 2014-08-15 2020-03-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
WO2016081649A1 (en) 2014-11-18 2016-05-26 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto
MA41803A (fr) 2015-03-24 2018-01-30 Almirall Sa Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
MX2018000352A (es) 2015-07-09 2018-08-15 Janssen Pharmaceutica Nv 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
KR20180108822A (ko) 2016-02-10 2018-10-04 얀센 파마슈티카 엔.브이. Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
CN110831593A (zh) 2017-06-14 2020-02-21 特维娜有限公司 用于调节s1p1活性的化合物及其使用方法
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
EP3774732A4 (en) 2018-04-04 2022-02-09 Janssen Pharmaceutica NV PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
CN110294756A (zh) 2019-06-04 2019-10-01 广州市原子高科同位素医药有限公司 GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备
SG11202112407PA (en) 2019-06-14 2021-12-30 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
AU2020291188A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators
UA129222C2 (uk) 2019-06-14 2025-02-12 Дебіофарм Інтернешнл С.А. Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою
BR112021025132A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Carbamatos de piridina e seu uso como moduladores do receptor glun2b
US20220324860A1 (en) 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
EP3983413A1 (en) * 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
AU2020290772A1 (en) 2019-06-14 2022-01-06 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
UY38806A (es) 2019-08-01 2021-02-26 Novartis Ag Compuestos inhibidores tricíclicos de kars dependientes de akr1c3, composiciones y sus usos
US20220348590A1 (en) * 2019-09-13 2022-11-03 The Board Institute, Inc. Cyclooxygenase-2 inhibitors and uses thereof
MX2022015703A (es) 2020-06-09 2023-01-24 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.

Also Published As

Publication number Publication date
US11993587B2 (en) 2024-05-28
US20200392113A1 (en) 2020-12-17
WO2020249802A1 (en) 2020-12-17
CA3143105A1 (en) 2020-12-17
CN114008052A (zh) 2022-02-01
BR112021024117A2 (pt) 2022-03-22
EP3983413A1 (en) 2022-04-20
US20220315590A1 (en) 2022-10-06
AU2020292994A1 (en) 2022-01-06
KR20220024403A (ko) 2022-03-03
US11214563B2 (en) 2022-01-04
JP2022536773A (ja) 2022-08-18

Similar Documents

Publication Publication Date Title
CR20210615A (es) Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
CR20210580A (es) Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
WO2020106642A8 (en) 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
MX2021015510A (es) Pirazolo[4,3-b]piridinas sustituidas y su uso como moduladores del receptor glun2b.
AU2018260809A1 (en) Compounds and uses thereof for the modulation of hemoglobin
AU2018260808A1 (en) Compounds and uses thereof for the modulation of hemoglobin
PH12022550359A1 (en) Nonpeptide somatostatin type 5 receptor agonists and uses thereof
NZ737399A (en) Ccr2 modulators
PH12020551144A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
PH12020551140A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
NZ757081A (en) Somatostatin modulators and uses thereof
MX2021015508A (es) Carbamatos de piridina y su uso como moduladores del receptor glun2b.
WO2019193516A3 (en) Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
MX2021015511A (es) Carbamatos de pirazina y sus usos como moduladores del receptor glun2b.
EP4427815A3 (en) Deuterium-enriched pirfenidone and methods of use thereof
EP4406957A3 (en) Aryl receptor modulators and methods of making and using the same
MX2022000712A (es) Moduladores de nlrp3.
WO2020106461A3 (en) Anti-mertk antibodies and methods of use thereof
MX2022011310A (es) Azabiciclo y derivados de diazepina para tratar trastornos oculares.
PH12021552838A1 (en) Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators